医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

TRADE NEWS: Agilent Technologies to Introduce Next-Generation UHPLC System at Analytica China on Sept. 23

2014年09月12日 AM11:00
このエントリーをはてなブックマークに追加


 

SANTA CLARA, Calif.

Agilent Technologies Inc. (NYSE:A) today announced it will introduce its latest innovation in ultra-high-performance liquid chromatography (UHPLC) on Sept. 23 at Analytica China, the international trade fair for laboratory technology, analysis, biotechnology and diagnostics held in Shanghai.

“We are pleased to introduce our newest UHPLC solution at this important scientific event,” said Stefan Schuette, vice president and general manager of Agilent’s Liquid Phase Separations Division. “This powerful new instrument will provide scientists with the superior quality and confidence they have come to expect from Agilent, combined with significant new features that will advance their work to the next level of achievement.”

The instrument will be unveiled at Shanghai’s New International Expo Center, Hall N2, Booth 2102. Agilent management and scientists will be at the booth throughout the event to discuss product features and specifications with visitors.

For more information about the upcoming launch, visit http://NextUHPLC.agilent.com, or join the social media conversation at #NextUHPLC.

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.

On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.

Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding the separation of Agilent’s electronic measurement business; future revenues, earnings and profitability; the future demand for the company’s products and services; and customer expectations. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of our customers’ businesses; unforeseen changes in the demand for current and new products, technologies, and services; customer purchasing decisions and timing, and the risk that we are not able to realize the savings expected from integration and restructuring activities.

In addition, other risks that Agilent faces include those detailed in Agilent’s filings with the Securities and Exchange Commission, including our latest Form 10-K and Form 10-Q. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.

CONTACT

Agilent Technologies Inc.
Susan Berg, +1 408-553-7093
susan_berg1@agilent.com

同じカテゴリーの記事 

  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表
  • The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report
  • Masimo创始人兼首席执行官Joe Kiani将在智利举行的全球患者安全峰会上谈论人工智能